Ci4CC’s 24th Symposium & Workshop set to focus on precision oncology powered by data intelligence

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Chaired by the University of Miami Sylvester Comprehensive Cancer Center, the 24th Cancer Centers Informatics Society (Ci4CC) Symposium will convene the nation’s leading designated and community cancer centers with a central focus on advancing precision oncology.

As the field continues to evolve, the integration of high-quality real-world data and advanced analytics has become essential to enabling smarter, faster, and more personalized treatment decisions. This workshop will explore how data intelligence—spanning genomics, proteomics, translational clinical data, artificial intelligence, and predictive modeling—is unlocking new opportunities to improve outcomes, streamline care delivery, and accelerate research across both academic and community settings.

Together, we will examine strategic frameworks, real-world applications, digital platforms, and the infrastructure needed to scale data-powered innovation in oncology. From data to impact, let’s chart the path forward.

About the 24th Cancer Center Symposium & Workshop

This fall, the Cancer Center Informatics Society will host its 24th Symposium, November 7–9 in Miami, bringing together leaders from NCI-Designated and Community Cancer Centers. The program will spotlight how precision oncology is transforming cancer care—from real-time multi-omics integration and biomarker-driven therapies to adaptive clinical trials and predictive modeling.

In support of advancing cancer research, the Cancer Center Informatics Society (Ci4CC) is offering complimentary booths for all cancer centers to showcase their institutions and share valuable shared resource services with one another. 

Attendees will connect with colleagues from academic medical centers, cancer institutes, life sciences and biotech companies, and national research networks to explore how precision oncology is enhancing diagnostic accuracy, accelerating clinical trial enrollment, and powering personalized treatment strategies.

Cartoon of three people "turning data into knowledge and knowledge into health."

Summit themes include:

  • AI in Childhood and AYA cancers
  • Digital Tumors for Precision Oncology
  • Data Infrastructure & Clinical Trial Matching
  • CCSG Shared Resources National Alliance 
  • Precision Medicine and AI
  • Population Sciences: Leveraging AI/ML and LLM Technologies to Deliver Ris Stratified Survivorship Care
  • Leveraging ctDNA Technology Towards Diagnostics and Therapeutics Management
  • Wearables and Precision Medicine 
  • Metabolomics and Proteomics and AI Applications
  • Precision Medicine and Genomics Variability in Solid Tumors
  • EMR-embedded Next-Generation CTMS

Access all conference details—including registration, hotel information, the latest agenda, free cancer center booth space, and sponsorship opportunities. 

Advancements in cancer research and clinical care are never achieved in isolation. That is why fostering collaborative networks is fundamental to our Initiatives Program and central to the Society’s mission.  In keeping with the focus of the conference, Ci4CC will be formally launching new and further expanding some of its latest national initiatives—including the CCSG Shared Resources Alliance in Informatics and Data Science—at this year’s Summit.


Stay informed about the conference and sign-up for ongoing webinar and lecture series in cancer informatics and technology downloads through www.ci4cc.org/events.

Stephen D. Nimer, MD
Chair, 24th Cancer Center Symposium; Director, Oscar de la Renta Endowed Chair in Cancer Research, Sylvester Comprehensive Cancer Center; Executive dean for research, Professor of medicine, biochemistry & molecular biology, Miller School of Medicine, University of Miami
Table of Contents

YOU MAY BE INTERESTED IN

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

“Bridge to Bahia” exhibit.Source: Sylvester Comprehensive Cancer CenterKaren Estrada, a survivor of acute myeloid leukemia, used visual art to communicate with her two boys while undergoing a bone marrow transplant at Sylvester Comprehensive Cancer Center. Because Estrada’s treatment required isolation, and her young children could not yet read and write, she sought out other creative vessels to foster closeness between them.
Stephen D. Nimer, MD
Chair, 24th Cancer Center Symposium; Director, Oscar de la Renta Endowed Chair in Cancer Research, Sylvester Comprehensive Cancer Center; Executive dean for research, Professor of medicine, biochemistry & molecular biology, Miller School of Medicine, University of Miami

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login